全文获取类型
收费全文 | 77篇 |
免费 | 1篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 1篇 |
临床医学 | 7篇 |
内科学 | 9篇 |
神经病学 | 2篇 |
外科学 | 23篇 |
综合类 | 1篇 |
预防医学 | 9篇 |
药学 | 4篇 |
肿瘤学 | 7篇 |
出版年
2020年 | 3篇 |
2019年 | 2篇 |
2017年 | 13篇 |
2016年 | 4篇 |
2015年 | 1篇 |
2013年 | 5篇 |
2012年 | 6篇 |
2011年 | 4篇 |
2010年 | 9篇 |
2009年 | 2篇 |
2008年 | 5篇 |
2007年 | 5篇 |
2006年 | 3篇 |
2005年 | 2篇 |
2004年 | 4篇 |
2003年 | 3篇 |
2002年 | 2篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1992年 | 1篇 |
排序方式: 共有78条查询结果,搜索用时 93 毫秒
1.
2.
3.
4.
5.
《Clinics in Podiatric Medicine and Surgery》2017,34(4):541-564
6.
7.
8.
9.
10.
Stein E 《Atherosclerosis. Supplements》2002,2(4):19-23; discussion 23-5
There is considerable evidence that more aggressive lowering of low-density lipoprotein (LDL) cholesterol is associated with increased benefits in reducing atherosclerotic disease burden, supporting the notion of 'the lower, the better.' However, achievement of currently recommended goals has proven difficult with lipid-lowering agents at the commonly used doses. Current options for achieving greater LDL cholesterol reductions include use of high doses of the most effective of the available statins and use of high or moderate statin doses in combination with agents that work in a complementary manner (e.g. bile acid sequestrants or niacin). Near-term options may include statins with increased LDL cholesterol-lowering effectiveness and better-tolerated secondary agents that can be combined with statin therapy. Rosuvastatin (Crestor, AstraZeneca) is a new statin that may prove to be of considerable utility in achieving greater LDL cholesterol reductions than are currently possible with existing statins. Recent phase III clinical trials have shown that this agent produces significantly greater LDL cholesterol reductions than atorvastatin, simvastatin, or pravastatin in patients with primary hypercholesterolemia and significantly greater reductions than the maximal dose of atorvastatin in patients with familial hypercholesterolemia. 相似文献